文献类型：期刊文献

中文题名：黄芪多糖联合顺铂处理降低Lewis肺癌移植瘤CD44表达并降低血清Ⅳ型胶原蛋白和透明质酸的水平

英文题名：Astragalus polysaccharides combined with cisplatin decreases the serum levels of CD44 and collagen type Ⅳ and hyaluronic acid in mice bearing Lewis lung cancer

作者：明海霞[1];陈彦文[2];张帆[3];王强[2];董晓丽[1];顾静[1];李杨[1]

第一作者：明海霞

机构：[1]甘肃中医学院生理教研室、甘肃省中药药理与毒理学重点实验室,甘肃兰州730000;[2]甘肃中医学院解剖教研室、甘肃省中药药理与毒理学重点实验室,甘肃兰州730000;[3]甘肃中医学院生物教研室、甘肃省中药药理与毒理学重点实验室,甘肃兰州730000

第一机构：甘肃中医药大学基础医学院（敦煌医学研究所）|甘肃中医药大学科研实验中心（甘肃省中医药标准化技术委员会秘书处）

年份：2015

卷号：31

期号：7

起止页码：909

中文期刊名：细胞与分子免疫学杂志

外文期刊名：Chinese Journal of Cellular and Molecular Immunology

收录：CSTPCD;;Scopus;北大核心:【北大核心2014】；CSCD:【CSCD2015_2016】；PubMed;

基金：甘肃省科技厅计划项目(1212RJZA093);甘肃省高校基本科研业务项目(2014年)

语种：中文

中文关键词：黄芪多糖;Lewis肺癌;顺铂;IV型胶原蛋白;透明质酸;CD44;增效减毒

外文关键词：astragalus polysaccharides; Lewis lung cancer; cisplatin; collagen type W; hyaluronic acid; CD44; attenuatedsynergy

摘要：目的观察黄芪多糖(APS)联合顺铂(cisplatin)对小鼠Lewis肺癌移植瘤生长、血清Ⅳ型胶原蛋白(Col4)和透明质酸(HA)含量及移植瘤细胞CD44表达的影响。方法 90只C57BL/6 J小鼠,设空白对照组10只,其余80只依次造模为荷瘤小鼠,并随机分为8组:模型组(等体积生理盐水)、顺铂阳性对照组(6 mg/kg顺铂)、(50、100、200)mg/kg APS组,联合用药组(顺铂剂量减半,APS各剂量同上)。于造模次日起各组分别腹腔注射等体积的药物0.3 m L。顺铂每周1次,其余药物每天1次,连续20 d。于第21天眼球取血,采用放免法测定血清Col4、HA的含量,采用免疫组织化学染色和图像分析方法检测移植瘤细胞中CD44的表达,并计算各组抑瘤率。结果顺铂组、(50、100、200)mg/kg APS组及联合用药组,小鼠Lewis肺癌移植瘤的抑瘤率分别为49.30%、17.21%、39.68%、42.98%、51.02%、57.21%、65.11%。各治疗组均可降低小鼠血清中Col4和HA含量,抑制移植瘤细胞CD44的表达。结论 APS能抑制小鼠Lewis肺癌细胞的生长,降低移植瘤细胞CD44的表达,减少血清中Col4和HA含量;与顺铂减半剂量联合使用后作用增强,说明APS对顺铂有一定的增效减毒功能。
Objective To observe the effects of Astragalus polysacchaddes （APS） combined with cisplatin on growth of Lewis lung cancer （LLC）, serum content of collagen type IV （Col4） and hyaluronic acid （HA）, and CD44 protein level in LLC-bearing mice. Methods C57BL/6J mice （n = 90） were randomly divided into 2 groups, tO mice for blank control group, and 80 mice for tumor-bearing group. The tumor-bearing group was then randomized into 8 subgroups, l0 mice for each subgroup. The tumor-bearing mice were treated by peritoneal injection of normal saline, 6 mg/kg cisplatin, 50, 100, 200 mg/kg APS, and 3 mg/kg cisplatin combined with 50, 100,200 mg/kg APS, respectively. APS （0.3 mL） was injected once a day from the first to the 20th day after LLC transplantation, and cisplatin of the same volume was injected once a week. On the 21st day, the blood was taken from the eyeballs of all experimental mice. Col4 and HA contents in serum were detected by radioimmunoassay. The expression of CD44 in transplanted tumor cells was determined by immunohistochemistry and image analysis. The inhibition rate of tumor growth was also counted. Results The inhibition rates of 6 mg/kg cisplatin, 50, 100,200 mg/kg APS, and 3 mg/kg cisplatin combined with 50, ]00,200 mg/kg APS on LLC growth in the mice were 49.30%, ]7.21%, 39.68%, 42. 98%, 51.02%, 57.21% and 65. H%, respectively. Compared with the control subgroup of the tumor-bearing group, cisplatin, APS and cisplatin combined with APS reduced significantly the Col4 and HA content in serum, and down-regulated the expression of CD44. Conclusion APS can inhibit the growth of LLC cells, reduce the Col4 and HAcontent in serum, down-regulate the expression of CD44 protein in LLC-bearing mice, and enhance the therapeutic effect when combined with cisplatin, indicating that it can decrease the toxicity of cisplatin against tumor.